TRAIL, CXCL10 and CCL2 plasma levels during long-term Interferon-beta treatment of patients with multiple sclerosis correlate with flu-like adverse effects but do not predict therapeutic response. (Q40172029)

From Wikidata
Jump to navigation Jump to search
scientific article published on 19 September 2007
edit
Language Label Description Also known as
English
TRAIL, CXCL10 and CCL2 plasma levels during long-term Interferon-beta treatment of patients with multiple sclerosis correlate with flu-like adverse effects but do not predict therapeutic response.
scientific article published on 19 September 2007

    Statements

    title
    TRAIL, CXCL10 and CCL2 plasma levels during long-term Interferon-beta treatment of patients with multiple sclerosis correlate with flu-like adverse effects but do not predict therapeutic response (English)
    1 reference
    stated in
    Europe PubMed Central
    PubMed publication ID
    17884184
    reference URL
    https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17884184%20AND%20SRC:MED&resulttype=core&format=json
    retrieved
    7 January 2020

    Identifiers

     
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    edit
                      Retrieved from "https://www.wikidata.org/w/index.php?title=Q40172029&oldid=2083269228"